

12 May 2015

ASX ANNOUNCEMENT

Chairman sells 7 million shares

The Chairman of Medical Developments Limited (ASX: MVP), Mr. David Williams has given notice that he sold 7 million shares this morning at \$2.40 to mainly Institutional investors in order to increase liquidity of the shares on the open market. Accordingly, the company expects a substantial shareholding notice from a large Australian Institution to be made shortly.

Mr. David Williams still remains a substantial shareholder of MVP, having a remaining indirect interest in 23,370,890 shares and as a consequence of this, we expect a 'Notice of Change of Interests of Substantial Shareholder' will soon be released.

Enquiries:

David Williams
Chairman
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
+61 (3) 9547 1888



About Pentrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.